Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 170,000 | 2.4% |
| Gross Profit | -5.4M | 31.9% |
| Cost of Revenue | 5.6M | 31.2% |
| Operating expense | 13M | 35.2% |
| Net Income | -14M | 264.3% |
| EBITDA | -13M | 35.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 103M | 13.1% |
| Total Liabilities | 26M | 9.7% |
| Total Equity | 76M | 14.2% |
| Shares Outstanding | 71M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -15M | 4.9% |
| Cash from investing | 290,000 | 97.7% |
| Cash from financing | 38,000 | 89.3% |
EPS
Financial Highlights for Ovid Therapeutics in Q3 '24
Ovid Therapeutics reported a revenue of 170,000, which is a 2.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -5.4M, marking a 31.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 5.6M, a -31.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 13M, showing a -35.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -14M, showing a -264.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -13M, showing a 35.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Ovid Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
